Results showed that subjects taking the extract were seeing significant improvements as early as five days into the trial, and post-trial, saw significant reductions of VAS, LFI, WOMAC pain, WOMAC stiffness, WOMAC function, and total WOMAC scores of 45%, 40.9%, 44.4%, 66.3%, 44.4%, and 48%, respectively.
A recent study1 found that a Boswellia serrata-based supplement called AprèsFlex 5-Day Joint Support from PLT Health Solutions Inc. (Morristown, NJ) helped alleviate pain in subjects with osteoarthritis in their knees. In the study, 70 subjects were given either placebo or 100 mg of AprèsFlex every day for 30 days. Subjects were evaluated for pain and physical function using Visual Analog Scale (VAS), Lequesne Functional Index (LFI), and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at the baseline, day 5, and day 30 of treatment.
Results showed that subjects taking AprèsFlex were seeing significant improvements as early as five says into the trial, and post-trial, saw significant reductions of VAS, LFI, WOMAC pain, WOMAC stiffness, WOMAC function, and total WOMAC scores of 45%, 40.9%, 44.4%, 66.3%, 44.4%, and 48%, respectively. Inflammatory and cartilage biomarkers were also assessed, and researchers found that subjects taking AprèsFlex has reductions in circulating matrix metalloproteinase-3, tumor necrosis factor-α, high-sensitive C-reactive protein, and collagen type II cleavage.
“When it comes to mobility, there can be a disconnect between what consumers want and what existing solutions deliver. Too often, natural joint and muscle health solutions require large doses that take weeks or even months to show improvements – and the science backing these ingredients doesn’t support what consumers are looking for,” said Seth Flowerman, president and CEO of PLT Health, in a press release. “That is one of the reasons we continually work to understand things like mechanism of action and to develop quality science that can support strong messaging.”
AprèsFlex is a patented, synergistic combination of two proprietary extracts derived from Boswellia serrata gum resin that PLT Health says has significantly higher oral bioavailability of acetyl-11-keto-beta-boswellic acid (AKBA) than other commercially available Boswellia extracts. This allows for an efficacious low daily dose. The current study confirms results from two previous study, demonstrating the ingredient’s efficacy.
“We now have three double-blind placebo-controlled clinical trials that validate the efficacy of AprèsFlex, and two demonstrating improvements as early as five days, at a low dose. These outcomes support our customers’ ‘fast-acting’ claims for their products containing AprèsFlex,” said Jeremy Appleton, ND, director of medical and scientific affairs at PLT Health.